Compound for the treatment of the hemolytic-uremic syndrome

The present invention relates to a compound and related pharmaceutical preparation, for use in the treatment and / or prevention of haemolytic uremic syndrome or in the treatment of a mammal having at least one Shiga toxin in the blood.

Patent title Compound for the treatment of the hemolytic-uremic syndrome
Thematic area Health
Inventors Elisabetta Galassi, Maurizio Brigotti, Domenica Carnicelli, Elisa Porcellini
Protection International
Licensing status Available for development agreements, option, license and other exploitation agreements
Keywords Escherichia coli, Shiga toxin, bacteria, syndrome, antibiotic, polymyxin
Filed on 23 December 2019

Shiga toxins are proteins produced by bacteria such as Escherichia coli and Shigella which constitute the fundamental pathogenicity factor for the development of haemolytic uremic syndrome (HUS). Hemolytic uremic syndrome is a serious sequela of these bacterial infections affecting approximately 10-15% of infected patients, mainly children under 3 years of age. There are no specific treatments for HUS, patients are treated only with supportive care.

Non-toxic derivative of the polymyxin antibiotic known as NAB815 and its use in the prevention and treatment of haemolytic uremic syndrome in patients infected with Shiga toxin-producing strains of Escherichia coli.

Decreased risk of nephrotoxicity, reduced need for dialysis and kidney transplantation.

Page published on: 21 December 2020